Skip to main navigation

Immunocore

Immunocore

Primary Menu

  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Document & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact Us

Primary Menu

  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Document & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact Us

News Releases

Breadcrumb

  1. Home /
  2. Investor Relations /
  3. News & Events /
  4. News Releases
2 December 2022
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
23 November 2022
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
11 November 2022
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
10 November 2022
Immunocore to present at the Jefferies London Healthcare Conference
9 November 2022
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
9 September 2022
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
10 August 2022
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
3 August 2022
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
1 August 2022
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
18 July 2022
Immunocore Announces $140 Million Private Placement Financing

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
Displaying 21 - 30 of 174

Site - Shareholder Tools

Print Page
Email Alerts
RSS Feeds
Email Page

Immunocore

Immunocore

Site - Footer Social

  • About us
  • Our science
  • Our therapy areas
  • For patients
  • News
  • Careers
  • Contact us
  • Privacy and Social Media Guidelines
  • Cookies
  • Payments and Disclosures
  • Clinical trials

©2023 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd